GlaxoSmithKline reported 5.57B in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Alcon AG ALC:SW 1.22B 144M
Amgen AMGN:US $ 4889M 478M
AstraZeneca AZN:LN 6.03B 627M
Bayer BAYN:GR 6.31B 1.32B
Biogen BIIB:US $ 2315.3M 99.4M
Bristol Myers Squibb BMY:US $ 9252M 682M
Eli Lilly And LLY:US $ 4786.9M 140.1M
Fresenius FRE:GR € 2618M 160M
Fresenius Medical Care FME:GR € 1284M 77M
Gilead Sciences GILD:US $ 4827M 235M
GlaxoSmithKline GSK:LN 5.57B 566M
Glaxosmithkline GSK:US $ 5573M 566M
GRIFOLS GRF:SM € 580.8M 47.47M
H. Lundbeck A/S LUN:DC 3.11B 200M
Hikma Pharmaceutical HIK:LN 616M 5M
Lonza Group LONN:SW 1.04B 418M
Merck MRK:GR € 3057M 147M
Merk MRK:US $ 8718M 93M
Novartis NOVN:VX 9.54B 679M
Orion ORNBV:FH 155.3M 1.3M
Pfizer PFE:US $ 11985M 1575M
Philips PHIA:NA € 1789M 302M
Recordati REC:IM 284.13M 3.36M
Regeneron Pharmaceuticals REGN:US $ 4444.8M 2224.1M